N-(α-Linolenoyl) Tyrosine – 5 mg

Brand:
Cayman
CAS:
259143-19-6
Storage:
-20
UN-No:
De Minimis - 1170 / 3

Certain chronic neurologic disorders, such as Parkinson’s disease, are caused by an insufficiency of the neurotransmitter dopamine secondary to the degeneration of substantia nigra dopaminergic neurons.{7161} N-(α-Linolenoyl) tyrosine (NALT) is a simple α-amide conjugate between the ω-3 essential fatty acid α-linolenate and the amino acid tyrosine. α-Linolenate is an important precursor to docosahexaenoic acid (DHA), a prominent brain polyunsaturated fatty acid, while tyrosine is the metabolic precursor for neuronal dopamine synthesis. NALT was prepared as a method for enhancing central nervous system (CNS) dopamine content by facilitated transport of the tyrosine precursor across the blood-brain barrier.{10323} In experimental rat models of dopamine insufficiency, NALT increased CNS dopamine levels and exhibited an activity profile consistent with an anti-Parkinson’s therapeutic agent.{10323}  

 

Available on backorder

SKU: 10032 - 5 mg Category:

Description

A simple α-amide conjugate between the ω-3 essential fatty acid α-linolenate and the amino acid tyrosine that was prepared as a mechanism for enhancing CNS dopamine content by facilitated transport of the tyrosine precursor across the blood-brain barrier; increased CNS dopamine levels and exhibited an activity profile consistent with an anti-Parkinson’s therapeutic agent in experimental rat models of dopamine insufficiency


Formal name: N-(L-tyrosine)-9Z,12Z,15Z-octadecatrienamide

Synonyms:  NALT

Molecular weight: 441.6

CAS: 259143-19-6

Purity: ≥98%

Formulation: A solution in ethanol


Product Type|Biochemicals|Lipids|Fatty Amides||Product Type|Biochemicals|Lipids|Octadecanoids||Research Area|Lipid Biochemistry|Fatty Acids||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease